Spinal cord injury (SCI) is an extremely serious type of physical trauma observed in clinics. Neuropathic pain resulting from SCI has a lasting and significant impact on most aspects of daily life. Thus, a better understanding of the molecular pathways responsible for the cause of neuropathic pain observed in SCI is important to develop effective therapeutic agents and treatment strategies. Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is well known for its critical roles in regulating protein synthesis and growth. Furthermore, compelling evidence supports the notion that widespread dysregulation of mTOR and its downstream pathways are involved in neuropathic pain. Thus, in this study we specifically examined the underlying mechanisms by which mTOR and its signaling pathways are involved in SCI-evoked neuropathic pain in a rat model. Overall, we demonstrated that SCI increased the protein expression of p-mTOR, and mTORmediated-phosphorylation of 4E-binding protein 4 (4E-BP1) and p70 ribosomal S6 protein kinase 1 (S6K1) in the superficial dorsal horn of the spinal cord. Also, we showed that blocking spinal mTOR by intrathecal injection of rapamycin significantly inhibited pain responses induced by mechanical and thermal stimulation. In addition, blocking spinal phosphatidylinositide 3-kinase (p-PI3K) pathway significantly attenuated activities of p-mTOR pathways as well as mechanical and thermal hyperalgesia in SCI rats. Moreover, blocking mTOR and PI3K decreased the enhanced levels of substance P and calcitonin gene-related peptide (CGRP) in the dorsal horn of SCI rats. We revealed specific signaling pathways leading to SCI-evoked neuropathic pain, including the activation of PI3K, mTOR and its downstream signaling pathways. Targeting one or more of these signaling molecules may present new opportunities for treatment and management of neuropathic pain often observed in patients with SCI. 
Introduction
Spinal cord injury (SCI) is an extremely serious type of physical trauma observed in medical practice and affects the quality of life of more than 2 million people worldwide [1] . One of the most common and distressing symptoms suffered by patients with SCI is chronic neuropathic pain. Thus, it is clinically important to develop effective therapeutic agents and treatment strategies for SCI patients suffering from neuropathic pain. In general, treatment options for these abnormal sensations have been restricted, partly due to a poor understanding of the underlying mechanisms responsible for neuropathic pain induced by SCI.
Notably, SCI leads to obvious changes in the synaptic circuits in the dorsal horn and the areas rostral to the site of injury through a variety of mechanisms [2] , such as abnormalities in the expression and activity of receptors and ion channels, release of local inflammatory cytokines and reactive oxygen species, activation of the immune response in microglia and other immune cells, and the activation of intracellular cascades. Nonetheless, the precise mechanisms remain to be elucidated.
Mammalian target of rapamycin (mTOR)
is a serine/threonine protein kinase.
Activation of mTOR, in particular mTOR complex 1 (mTORC1), which is more sensitive to rapamycin, leads to promotion of the phosphorylation of downstream effectors, such as p70 ribosomal S6 protein kinase (p70S6K) and this further governs mRNA translation [3] . Thus, mTORC1 is well known to play a critical role in regulating protein synthesis and growth [4, 5] .
In addition, prior studies have strongly supported the notion that mTOR plays an important role in the modulation of longterm neuronal plasticity [6, 7] . Specifically, Therefore, we suspected that mTOR is likely an important player for the induction and maintenance of SCI induced-neuropathic pain.
As a key region of pain regulation [12] , the spinal cord dorsal horn is likely engaged in the effects of mTOR on SCI-induced pain [10] . We specifically hypothesized that SCI increases the protein expression of mTOR and its downstream pathways in the superficial dorsal horn, resulting in mechanical and thermal hypersensitivity.
Blocking mTOR pathways attenuates pain responses evoked by mechanical and thermal stimulation. We also hypothesized that blocking spinal phosphatidylinositide 3-kinase (PI3K) attenuates activities of mTOR pathways, thereby leading to a reduction in mechanical and thermal sensitivity.
Substance P and calcitonin gene-related peptide (CGRP) are excitatory neurotransmitters and (or) neuromodulators that are released in the dorsal horn of the spinal dorsal horn by the primary sensory afferents, thereby contributing to the development of allodynia and hyperalgesia by facilitating the release of excitatory glutamate and aspartate from primary afferents [13] . Thus, we further hypothesized that blocking mTOR and PI3K pathways attenuates the amplified levels of substance P and CGRP in the dorsal horn of rats with SCI. In the absence of a response, the filament of next greater force was applied. To avoid injury during tests, the cutoff strength of the von Frey filament was 18 g. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the "up-down" method [17] . Each trial was repeated two times at approximately 2 min intervals. The mean value was used as the force producing a withdrawal response [18] .
Materials and methods

Animals
To determine thermal hyperalgesia, rat paw withdrawal latency (PWL) to a radiant heat was measured as described previously [19] . Rats were placed individually in plastic cages on an elevated glass platform and allowed for 30 min acclimation. Each hind paw received three stimuli with a 10 min interval, and the mean of the three withdrawal latencies was defined as PWL. The heat was maintained at a constant intensity. To prevent tissue damage, the cut-off latency was set at 20 s. All the behavioral tests were performed in a blind style.
Western blot analysis
The rats were euthanized and the superficial dorsal horn (lumbar 4-6) tissues were dissected under an anatomical microscope. 
ELISA measurements
To examine the levels of substance P and CGRP in the superficial dorsal horn of the spinal cord (L4-L6), enzyme-linked immunosorbent assay (ELISA) methods were employed. Substance P was measured using substance P ELISA kit following the manufacturer's instructions (Abcam Company, Cambridge, UK). Briefly, the diluted tissue supernatant (100 μl) was placed in a 96-well goat anti-mouse IgGcoated plate and incubated for 2 hours. After incubation, the plate was washed using the provided washing buffer, and the color was developed by adding p-nitrophenyl phosphate (pNPP, 200 μl) substrate after 45 min and determined by an ELISA plate reader.
The amount of substance P was calculated by using a substance P standard curve. In a similar way, the CGRP content of the samples (100 μl supernatant) was determined using a commercial CGRP ELISA kit (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, the diluted samples were placed in a 96-well plate incubated with pre-coated anti-rat IgG antibody overnight, washed and developed, and quantified [20] .
Statistical analysis
All data were analyzed using a one-way analysis of variance. Values were presented as means ± standard deviation (SD). For all analyses, differences were considered significant at level of α < 0.05. All statistical analyses were performed by using SPSS for Windows version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
First, we examined responses to the mechanical and thermal stimulation prior to SCI surgery in order to obtain baseline values (number of rats = 79). Basal PWT was 15.5 ± 4.5 g (means ± SD) and basal PWL was 13.3 ± 3.2 s (means ± SD).
Mechanical allodynia and thermal hyperalgesia began to appear 2 weeks after induction of SCI and lasted for 4 weeks. In those rats, PWT was 5.4 ± 1.5 g (means ± SD; P = 0.0085 vs. baseline) and PWL was 5.5 ± 1.7 s (means ± SD; P = 0.0078 vs. baseline) 4 weeks following SCI. Animals (~5%) that did not display increases in mechanical and thermal sensitivity of at least 40% of baseline values were excluded from the experiment [14] . In general, about 90-95% of rats that receive SCI procedures display pain responses and they are considered to be included in the study [14, 21] .
Effects of mTOR and PI3K on SCIinduced hyperalgesia After mechanical and thermal hyperalgesia were well established in rats, rapamycin and LY294002 were intrathecally injected. A. Typical bands and averaged data showing that p-mTOR, p-S6K1 and p-4E-BP1 in the dorsal horn of the spinal cord were upregulated in SCI rats. *all P values <0.05 vs. control rats (number of rats = 6-10 in control and SCI). There were insignificant differences in total protein expression of mTOR, S6K1 and 4E-BP1 in control rats and SCI rats (number of rats = 6-10). B. Typical bands and averaged data showing expression of p-mTOR/mTOR and p-S6K1/S6K1 were amplified in the dorsal horn of SCI rats with vehicle treatment (number of rats = 6-10) as compared with control rats (number of rats = 6-8). Blocking PI3K pathways by LY294002 attenuated increases in p-mTOR and p-S6K1 in SCI rats. *all P values <0.05 vs. control animals and SCI animals infused with LY294002 (number of rats = 6-10 in each group). 
Discussion
There are two distinct mTOR forms of protein complexes, mTOR complex 1 (mTORC1) and mTORC2. In general, mTORC1 is composed of raptor, mLST8, and mTOR, and is known to function by gate translation of most proteins by phosphorylation of specific downstream effectors including, 4E-BPs and p70 ribosomal S6Ks [22] . mTOR, S6K1, and 4E-BP1 are expressed in the mammalian nervous system, particularly in spinal cord dorsal horn [7, 22] .
Because the superficial dorsal horn is the first synaptic site from peripheral afferent nerves to the central nervous system [23, 24] and plays an important role in modulating pain and morphine tolerance [12, 25] , in this study It should be noted that in general, about 90-95% of rats that receive SCI procedures display pain responses and they are considered to be included in the study [14, 21] . Accordingly, in our current report, 5% of rats that did not display increases in responses to mechanical and thermal stimulation were excluded from the experiment. Figure 3. Effects of blocking mTOR and PI3K pathways on the levels of substance P and CGRP in the superficial dorsal horn of the spinal cord. SCI significantly increased substance P and CGRP as compared with controls and blocking mTOR and PI3K by rapamycin and LY294002 significantly attenuated the enhancement in substance P and CGRP evoked by SCI. Note that a greater inhibitory effect on substance P and CGRP was observed by LY294002. *P = 0.0081 (for substance P) and P = 0.0093 (for CGRP), indicated SCI rats (number of rats = 15) vs. control rats (number of rats =15) and SCI rats with rapamycin (n=10) and LY294002 (number of rats =10) injection.
# P = 0.017 (for substance) and P = 0.012 (for CGRP), indicated SCI rats with rapamycin injection vs. with LY294002 injection.
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